scholarly journals The Effect of Buddleja officinalis Maxim Eye Drops on Morphology and Apoptosis in Lacrimal Gland of Experimental Dry Eye Rabbit Model

2019 ◽  
Vol 2019 ◽  
pp. 1-7
Author(s):  
Genyan Qin ◽  
Yasha Zhou ◽  
Jun Peng ◽  
Youwei Zhang ◽  
Xiaofang Peng ◽  
...  
Keyword(s):  
Dry Eye ◽  
Lacrimal Gland ◽  
Rabbit Model ◽  
Morphological Structure ◽  
Study Groups ◽  
Control Group ◽  
Eye Drops ◽  
Model Group ◽  
Lacrimal Glands ◽  
Eye Model

The purpose of this study was to investigate the effects of Buddleja officinalis Maxim eye drops on morphology and apoptosis in lacrimal glands of the experimental dry eye rabbit model. A total of thirty-six male rabbits were divided into six study groups, consisting of the control group and the dry eye rabbit model group (without any treatment), the dry eye rabbit model group treated with testosterone, and the dry eye rabbit model group treated with different concentrations of Buddleja officinalis Maxim eye drops (1.0 mg/ml, 1.5 mg/ml and 3.0 mg/ml). The lacrimal glands were evaluated by hematoxylin-eosin staining and immunohistochemistry. Buddleja officinalis Maxim eye drops can improve the morphological structure of the lacrimal gland in the dry eye model of castrated rabbits. The average optical density values of PI3K, Akt, and caspase-9 protein in the lacrimal gland tissue of the 3 mg/ml Buddleja officinalis Maxim eye drops group were significantly different from those in the model group (P<0.01) and similar to the testosterone control group and the control group (P>0.05). Buddleja officinalis Maxim eye drops can improve the morphological structure of the lacrimal gland in the dry eye model of castrated rabbits.

scholarly journals Astragalus Ⅳ ameliorates the dry eye injury in rabbit model via MUC1-ErbB1 pathway

2021 ◽  
Vol 65 (2) ◽  
Author(s):  
Li Chu ◽  
Suhong Ma ◽  
Zhiwei Chen ◽  
Wenfu Cao
Keyword(s):  
Dry Eye ◽  
Rabbit Model ◽  
Immunofluorescent Staining ◽  
Bulbar Conjunctiva ◽  
Therapeutic Effects ◽  
Eye Drops ◽  
Protective Agent ◽  
Model Group ◽  
Astragaloside Iv ◽  
Schirmer Tear Test

The therapeutic effects and potential mechanisms of astragaloside IV on a rabbits dry eye model induced by benzalkonium chloride (BAC) was examined. In our study, a BAC-induced dry eye rabbit model was treated with eye drops containing astragaloside IV (5, 10 μM) or solvent four times a day. The clinical evaluations, such as tear break-up time (BUT) and Schirmer tear test (STT), were performed on days 0, 7, 14, 21, and 28. On day 28, the cornea and bulbar conjunctiva tissues (left eye and right eye) were collected with histology, and immunofluorescent staining conducted. The levels of MUC1 and ErbB1in the corneas were determined by real-time quantitative PCR (qRT-PCR) and the proteins levels of MUC1 and ErbB1 were detected by Western blot. It was demonstrated that both astragaloside IV (5, 10 μM) treatments resulted in an increased STT and BUT on days 7, 14, 21 and 28. Additionally, the astragaloside IV (5, 10 μM)-treated group showed increasing PAS-positive goblet cells than model group (0 μM). Moreover, the MUC1 in model group (0 μM) was decreased, while the expression of MUC1 in astragaloside IV (5, 10 μM) group was increased. Furthermore, astragaloside IV had a protective effect on BAC-induced rabbits’ dry eye and demonstrated clinical improvements, which indicated that astragaloside IV served as a potential protective agent in the clinical treatment of dry eye.

scholarly journals Refractory Dry Eye Syndrome after Transconjunctival Excision of the Palpebral Lobe of the Lacrimal Gland

Medicina ◽  
2021 ◽  
Vol 57 (6) ◽  
pp. 608
Author(s):  
Yong-Jae Lee ◽  
Han-Sol Choi ◽  
Seong-Jun Park ◽  
Hae-Jung Sun ◽  
Sun-Young Jang
Keyword(s):  
Female Patient ◽  
Dry Eye ◽  
Lacrimal Gland ◽  
Medical Center ◽  
Chief Complaint ◽  
Incisional Biopsy ◽  
Lacrimal Glands ◽  
Palpable Mass ◽  
Tear Secretion ◽  
Palpebral Lobe

The aim of the present study was to report two cases of refractory dry eye syndrome (DES) after transconjunctival excision of the palpebral lobe of the lacrimal gland. A 25-year-old female patient with a chief complaint of a palpable mass in both upper eyelids visited our medical center. Preoperative orbital computer tomography showed high-attenuation lesions in both lacrimal glands. Incisional biopsy of the lacrimal gland palpebral lobe via transconjunctival incision was performed in January 2019. At 1 month after the biopsy, a lack of tears and persistent corneal erosions were found in both eyes. Artificial tears, punctal occlusion, autologous serum eye drops, and therapeutic contact lenses were applied in an attempt to control the dry eye symptoms. The patient continues to suffer from intractable DES at 2.5 years after the procedure. The second case involved a 52-year-old female patient who visited our medical center with a chief complaint of a palpable mass in both upper eyelids. Bilateral orbital tumors were diagnosed with preoperative magnetic resonance imaging. An incisional biopsy of the lacrimal gland was performed. Immunoglobulin G4-related dacryoadenitis was confirmed through lacrimal palpebral lobe incisional biopsy. Intractable DES and corneal erosion of her left eye persisted thereafter. A transconjunctival incision is an effective approach for minimizing postoperative scars and is suitable for the biopsy of tumors that are visible through the conjunctiva. After a biopsy of the palpebral lobe of the main lacrimal glands, the secretion of reflex tears decreases due to damage to the secreting ducts of the main lacrimal glands. However, total tear secretion can be maintained by basal tear secretion from the accessory lacrimal glands. In this report, we describe two cases of refractory DES due to decreased total tear secretion, although only the palpebral lobes of the main lacrimal glands were biopsied.

scholarly journals The Effect of Intravitreal Azithromycin on the Albino Newborn Rabbit Retina

2016 ◽  
Vol 10 (1) ◽  
pp. 12-16
Author(s):  
Duygu Cam ◽  
Ali Osman Saatci ◽  
Serap Cilaker Micili ◽  
Bekir Ugur Ergur ◽  
Revan Yildirim Karabag ◽  
...  
Keyword(s):  
Light Microscopy ◽  
Caspase 3 ◽  
Rabbit Model ◽  
Study Groups ◽  
Terminal Deoxynucleotidyl Transferase ◽  
Control Group ◽  
Tunel Staining ◽  
Rabbit Retina ◽  
Newborn Rabbit ◽  
The Right

Purpose: To evaluate the effect of intravitreal azithromycin on the retina in a newborn rabbit model. Methods: Twelve, two-week old New Zealand albino rabbits were divided into two groups (six in each). The right eyes of six rabbits received 0.75 mg (0.05 mL) azithromycin and the right eyes of the remaining six rabbits 1.5 mg (0.1 mL) azithromycin intravitreally. Left eyes were served as the control and received the same volume of saline. All eyes were enucleated at the third postinjection week. Retinal histology was examined by light microscopy. Apoptosis of the retinal cells was further evaluated by immunohistochemical staining for caspase-3 and in situ terminal deoxynucleotidyl transferase-mediated biotin-deoxyuridine triphosphate nick-end labeling (TUNEL) of DNA fragments. Results: Light microscopy demonstrated no retinal abnormalities in all eyes. However, retinal nuclear DNA fragmentation was evident in both study groups (33.6% with 1.5 mg and 21.4% with 0.75 mg azithromycin) with the TUNEL method. TUNEL staining ratio was statistically higher only in the second group treated with 1.5 mg azithromycin when compared to the control group (p=0.01 Mann Whitney U test). The ratio of caspase-3 positive cells in the two study groups was 21.5% and 20.2%, respectively. Caspase-3 staining ratio was statistically higher in both study groups when compared to the control eyes (p=0.00, p=0.00 respectively). The difference of TUNEL staining ratio between the two study groups was statistically significant (p=0.028), but there were no statistically significant differences in the two study groups by caspase-3 staining (p=0.247). Conclusion: In newborn rabbits, intravitreal azithromycin injection resulted in an apoptotic activity in the photoreceptor, bipolar and ganglion cells. Immunohistochemical analysis suggested that doses of 0.75 mg and 1.5 mg azithromycin, administered intravitreally might be toxic to the newborn rabbit retina.

scholarly journals Effects of Topical Gabapentin on Ocular Pain and Tear Secretion

2021 ◽  
Vol 12 ◽  
Author(s):  
Maurizio Cammalleri ◽  
Rosario Amato ◽  
Melania Olivieri ◽  
Salvatore Pezzino ◽  
Paola Bagnoli ◽  
...  
Keyword(s):  
Lacrimal Gland ◽  
Ocular Surface ◽  
Rabbit Model ◽  
Corneal Epithelial Cell ◽  
Epithelial Cell Line ◽  
Eye Drops ◽  
Aquaporin 5 ◽  
Ocular Pain ◽  
Anesthetic Drugs ◽  
Anti Inflammatory

Neuropathic ocular pain is a frequent occurrence in medium to severe dry eye disease (DED). Only palliative treatments, such as lubricants and anti-inflammatory drugs, are available to alleviate patients’ discomfort. Anesthetic drugs are not indicated, because they may interfere with the neural feedback between the cornea and the lacrimal gland, impairing tear production and lacrimation. Gabapentin (GBT) is a structural analog of gamma-amino butyric acid that has been used by systemic administration to provide pain relief in glaucomatous patients. We have already shown in a rabbit model system that its topic administration as eye drops has anti-inflammatory properties. We now present data on rabbits’ eyes showing that indeed GBT given topically as eye drops has analgesic but not anesthetic effects. Therefore, opposite to an anesthetic drug such as oxybuprocaine, GBT does not decrease lacrimation, but–unexpectedly–even stimulates it, apparently through the upregulation of acetylcholine and norepinephrine, and by induction of aquaporin 5 (AQP5) expression in the lacrimal gland. Moreover, data obtained in vitro on a primary human corneal epithelial cell line also show direct induction of AQP5 by GBT. This suggests that corneal cells might also contribute to the lacrimal stimulation promoted by GBT and participate with lacrimal glands in the restoration of the tear film, thus reducing friction on the ocular surface, which is a known trigger of ocular pain. In conclusion, GBT is endowed with analgesic, anti-inflammatory and secretagogue properties, all useful to treat neuropathic pain of the ocular surface, especially in case of DED.

Comparative analysis of incidence of dry eye syndrome after ReLEx SMILE and FemtoLASIK keratorefractive surgeries

2021 ◽  
pp. 192-196
Author(s):  
A.D. Pilipenko ◽  
◽  
R.A. Burya ◽  
A.V. Romanova ◽  
E.L. Sorokin ◽  
...  
Keyword(s):  
Dry Eye ◽  
Ocular Surface ◽  
Refractive Surgery ◽  
Photorefractive Effect ◽  
Study Groups ◽  
Dry Eye Syndrome ◽  
Control Group ◽  
Significant Difference ◽  
Negative Effect ◽  
Breakup Time

The main factor in pathogenesis of postoperative dry eye syndrome (DES) is damage to subbasal nerve plexus and stromal nerve endings. Taking into account the different principles of photorefractive effect on cornea of FemtoLASIK and ReLEx SMILE technologies, we decided on our own clinical experience to evaluate incidence of this undesirable complication. Purpose. Comparative study of frequency and timing of relief of postoperative DES after FemtoLASIK and ReLEx SMILE in patients with myopia. Material and methods. The study involved 32 patients (64 eyes) with varying degrees of myopia. The patients were divided into 2 groups: 1st group - 17 patients (34 eyes) after FemtoLASIK surgery, 2nd group - 15 people (30 eyes) after ReLEx SMILE procedure. Control group consist of 15 patients with comparable myopia who had not undergone refractive surgery was also observed. Patients underwent an assessment of the OSDI index, Norn and Schirmer tests, as well as degree of staining of anterior ocular surface 1, 6 and 12 months after refractive surgery. Results. There was statistically significant difference in total tear production, in tear breakup time (TBUT) and in the OSDI index between study groups 1 month after surgery in favor of ReLEx SMILE procedure. After 6 months, TBUT after FemtoLASIK significantly differed from control values. 12 months after surgery, studied parameters did not differ significantly from control. Conclusion. According to our datas, ReLEx SMILE procedure has lower negative effect on ocular surface compared to FemtoLASIK technique, which is manifested by less pronounced subjective symptoms of DES, as well as their faster relief. Key words: dry eye syndrome, ReLEx SMILE, FemtoLASIK.

Preservation of Tear Film Integrity and Inhibition of Corneal Injury by Dexamethasone in a Rabbit Model of Lacrimal Gland Inflammation–Induced Dry Eye

2005 ◽  
Vol 21 (2) ◽  
pp. 139-148 ◽  
Author(s):  
Teann J. Nagelhout ◽  
Daniel A. Gamache ◽  
Leighann Roberts ◽  
Milton T. Brady ◽  
John M. Yanni
Keyword(s):  
Dry Eye ◽  
Lacrimal Gland ◽  
Rabbit Model ◽  
Tear Film ◽  
Corneal Injury

scholarly journals Ultrasonic Predictors of Dry Eye Syndrome in Sarcoidosis

2019 ◽  
Vol 100 (4) ◽  
pp. 186-191
Author(s):  
T. N. Safonova ◽  
S. I. Kharlap ◽  
O. V. Eksarenko
Keyword(s):  
Dry Eye ◽  
Lacrimal Gland ◽  
Structural Changes ◽  
Dry Eye Syndrome ◽  
Tubular Structures ◽  
Lacrimal Glands ◽  
Acoustic Structure ◽  
Different Types ◽  
Systemic Sarcoidosis ◽  
Vascularization Index

Objective. To identify clinical and morphofunctional changes in the lacrimal gland in sarcoidosis.Material and methods. Ultrasonography was conducted in 53 patients (106 eyes) with a verified diagnosis of systemic sarcoidosis (7 men and 46 women) whose age was 31 to 72 years.Results. Different types of lacrimal gland structural changes in sarcoidosis were detected. Comparing the acoustic and functional findings revealed a high correlation (r > 0.7) between these parameters as vascularization index, a reflex component of tear secretion, and the presence of tubular structures. Types of changes in the acoustic structure of the lacrimal glands were identified, which were designated as edematous and polymorphic changes, as well as atrophic changes with a necrotic component.Conclusion. The findings can be used to diagnose lacrimal gland changes in patients suffering from sarcoidosis.

scholarly journals “Keratrop” eye drops efficacy in dry eye syndrome treatment in diabetic patients

The Eye ◽  
2020 ◽  
Vol 22 (4(132)) ◽  
pp. 36-41
Author(s):  
F. A. Bakhritdinova ◽  
F. A. Haydarova ◽  
K. I. Narzikulova ◽  
I. F. Nabieva
Keyword(s):  
Diabetes Mellitus ◽  
Dry Eye ◽  
Tear Film ◽  
Dry Eye Syndrome ◽  
Control Group ◽  
Diabetic Patients ◽  
Eye Drops ◽  
Artificial Tears ◽  
Antidiabetic Treatment ◽  
Patients With Diabetes

Significance. Prevalence of diabetes mellitus (DM) is increasing worldwide. People with diabetes are at higher risk to dry eye syndrome (DES). The increasing dependence of society on computers, air conditioning, and visual workload, etc. results in an increase in the manifestations of DES in diabetic patients. A significant part of the socially active population with diabetes requires prescription of drugs aimed at correcting disorders associated with both hyperglycemia and dry eyes. Conservative treatment of DES in case of diabetes includes prescription of artificial tears, metabolic, immunocorrecting, hormonal, antiallergic therapies as well as treatment of meibomian gland dysfunction (MGD). The tear substitutes, however, cannot always satisfy the needs of doctors and patients due to the imperfections of their formulas. Therefore, more and more new drugs are introduced to the market that require a comprehensive assessment.Purpose. To evaluate the clinical efficacy of Keratrop eye drops – a new artificial tear formulation – in dry eye syndrome treatment in patients with diabetes mellitus (DM).Methods. The study included 65 patients (130 eyes) with dry eye syndrome stages I and II associated with mild and moderate diabetes. These were adult patients of both sexes who had not previously received artificial tears as treatment and were undergoing either inpatient or domiciliary care. All studied patients provided a written informed consent and were divided into 2 groups by random sampling. The main group (35 patients) was receiving Keratrop instillations 2 times a day during 14 days, in the course of antidiabetic treatment. Instillations of “artificial tear” were not prescribed to patients of the control group (30 patients), and they only received antidiabetic treatment prescribed by the endocrinologist. Before and after treatment, all patients underwent standard ophthalmic examinations, meibography imaging, tear film assessment and filled in OSDI questionnaires.Results. The study showed that during treatment, in patients of the experimental group – with both I and II dry eye syndrome stages – a significant decrease in subjective and objective manifestations was observed, along with an improvement in the tear film stability. In the control group, positive dynamics was observed only in patients with the first stage of dry eye syndrome.Conclusion. Dry eye syndrome treatment in patients with diabetes should be comprehensive and must include both basic antidiabetic therapy and instillation of tear substitutes.

Sign in / Sign up

Export Citation Format

Share Document